Lilly’s Forteo Not A “Rational Choice” For Most Osteoporosis, Analysis Finds
Executive Summary
Lilly's osteoporosis treatment Forteo (teriparatide) would be cost-effective if the product were 60% cheaper and used sequentially with Merck's Fosamax (alendronate), according to a study published in the Archives of Internal Medicine
You may also be interested in...
Osteoporosis Drugs Found To Be Equally Effective – AHRQ Report
An Agency for Healthcare Research & Quality draft report on osteoporosis treatments found that bisphosphonates are not demonstrably superior to less costly treatments
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials